Literature Scan

Literature Scan

New and noteworthy research from the medial literature landscape

Oral Apixaban Noninferior to Subcutaneous Dalteparin for Preventing Recurrent Cancer-Associated VTE

In patients with cancer-associated venous thromboembolism (VTE), treatment with oral apixaban was noninferior to subcutaneous dalteparin for the prevention of recurrent VTE, according to...

Subcutaneous Daratumumab is Noninferior to IV Administration in Relapsed/Refractory Myeloma

Subcutaneous daratumumab was found to be noninferior to intravenous (IV) daratumumab in patients with relapsed or refractory multiple myeloma (MM), according to results from...

Abnormal Coagulation Parameters Associated With Mortality in Severe Coronavirus Pneumonia

Disseminated intravascular coagulation (DIC), marked by elevated D-dimer and fibrin degradation products (FDP), is associated with a higher risk of mortality in patients with...

UGT1A1*28 Genotype Is Associated With Reduced Overall Survival in Intermediate-Risk AML

Patients with intermediate-risk acute myeloid leukemia (AML) who are treated with cytarabine-based chemotherapy have lower overall survival (OS) if they possess the low-activity UGT1A1*28...

New Research Identifies W491 as a Potential Therapeutic Target in Essential Thrombocythemia

In patients with familial essential thrombocythemia (ET) negative for JAK2, CALR, or MPL W515 mutation (triple-negative), newly identified MPL mutations elucidate a broad mechanism...

Ropeginterferon Alfa-2b Leads to More Durable Responses Than Hydroxyurea in PV

Patients with polycythemia vera were more likely to achieve durable long-term hematologic response with ropeginterferon alfa-2b than the standard cytoreductive therapy hydroxyurea, according to...

Venetoclax Plus High-Dose Cytarabine With or Without Idarubicin Well Tolerated in Pediatric AML

In a small study of children and young adults with relapsed or refractory acute myeloid leukemia (AML), venetoclax plus cytarabine chemotherapy, with or without...

Comparing Risks of Hypophosphatemia With Intravenous Formulations in Iron-Deficiency Anemia

For patients with iron-deficiency anemia who are intolerant of or unresponsive to oral iron, intravenous formulations can rapidly correct iron deficiency, but certain formulations...

Venetoclax Plus Low-Dose Cytarabine Improves Survival and Remission in Patients With Chemotherapy-Ineligible AML

Treatment with venetoclax plus low-dose cytarabine (LDAC) led to greater improvements in remission and overall survival (OS), compared with LDAC alone, in patients with...

Clonal Hematopoiesis, Aberrant CD7 Expression Linked to Post-AHCT Therapy-Related Myeloid Neoplasms

Low variant allele frequency (VAF) clonal hematopoiesis, aberrant CD7 expression on hematopoietic stem cells, and specific gene mutations at the time of autologous hematopoietic...
Advertisement

Current Issue

July 2020 Volume 6 Issue 8

This issue discusses palliative care and hematopoietic cell transplant, examines anticoagulation in patients with obesity, and more.